研究者業績

佐田 尚宏

サタ ナオヒロ  (Naohiro Sata)

基本情報

所属
自治医科大学 医学部外科学講座 消化器一般移植外科学部門 主任教授 (附属病院 病院長)
(兼任)病院長
学位
医学博士(東京大学)

J-GLOBAL ID
200901010372664634
researchmap会員ID
1000300013

学歴

 2

論文

 556
  • 須藤 慧多, 太白 健一, 太田 学, 佐田友 藍, 田原 真紀子, 廣田 由佳, 福嶋 敬宜, 杉原 夏子, 味村 俊樹, 鯉沼 広治, 堀江 久永, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本消化器病学会関東支部例会プログラム・抄録集 369回 44-44 2022年5月  
  • Jun Watanabe, Atsushi Miki, Yasunaru Sakuma, Kentaro Shimodaira, Yuichi Aoki, Yoshiyuki Meguro, Kazue Morishima, Kazuhiro Endo, Hideki Sasanuma, Alan Kawarai Lefor, Takumi Teratani, Noriyoshi Fukushima, Joji Kitayama, Naohiro Sata
    Cancers 14(9) 2022年4月28日  
    BACKGROUND: Osteopenia is defined as low bone mineral density (BMD) and has been shown to be associated with outcomes of patients with various cancers. The association between osteopenia and perihilar cholangiocarcinoma is unknown. The aim of this study was to evaluate osteopenia as a prognostic factor in patients with perihilar cholangiocarcinoma. METHODS: A total of 58 patients who underwent surgery for perihilar cholangiocarcinoma were retrospectively analyzed. The BMD at the 11th thoracic vertebra was measured using computed tomography scan within one month of surgery. Patients with a BMD < 160 HU were considered to have osteopenia and b BMD ≥ 160 did not have osteopenia. The log-rank test was performed for survival using the Kaplan-Meier method. After adjusting for confounding factors, overall survival was assessed by Cox's proportional-hazards model. RESULTS: The osteopenia group had 27 (47%) more females than the non-osteopenia group (p = 0.036). Median survival in the osteopenia group was 37 months and in the non-osteopenia group was 61 months (p = 0.034). In multivariable analysis, osteopenia was a significant independent risk factor associated with overall survival in patients with perihilar cholangiocarcinoma (hazard ratio 3.54, 95% confidence interval 1.09-11.54, p = 0.036), along with primary tumor stage. CONCLUSIONS: Osteopenia is associated with significantly shorter survival in patients with perihilar cholangiocarcinoma.
  • Jun Watanabe, Atsushi Miki, Hideki Sasanuma, Kazuhiko Kotani, Naohiro Sata
    Journal of Hepato-Biliary-Pancreatic Sciences 2022年4月24日  
  • Hirokazu Matsuura, Akira Saito, Yusuke Amano, Kazue Morishima, Hideki Sasanuma, Alan Kawarai Lefor, Naohiro Sata
    International journal of surgery case reports 94 107085-107085 2022年4月13日  
    INTRODUCTION AND IMPORTANCE: Intussusception is invagination of the bowel and is rare in adults, representing only 5% of all cases of intussusception. Duodenal intussusception is also very rare. To the best of our knowledge, there is only one previous report of a malignant tumor in the fourth portion of the duodenum as the lead point of intussusception (Vaibhav et al., 2021 [1]). This reports a duodenal-duodenal intussusception caused by a malignant tumor in the third portion of the duodenum. CASE PRESENTATION: A 36-year-old woman with abdominal pain was diagnosed with duodenal intussusception by abdominal ultrasonography and computed tomography scan. Double balloon endoscopy showed that the intussusception had spontaneously reduced, and a tumor was found in the third portion of the duodenum. Open resection was performed because of the tumor location. Pathologic examination revealed adenocarcinoma with an adenoma of the duodenum. The patient had no evidence of recurrence for 4 years after resection. CLINICAL DISCUSSION: This patient had a primary duodenal malignancy and presented with intussusception, Duodenal intussusception is a rare condition requiring prompt intervention, usually requiring surgery. In this patient, since endoscopic resection was difficult, partial resection of duodenum was performed by open surgery assisted by double balloon enteroscopy. The pathological diagnosis of the resected specimen was primary duodenal malignancy. CONCLUSION: This is a report of adult duodenal intussusception caused by a primary duodenal malignancy. This rare condition posed an intriguing challenge for the optimal operative approach.
  • 小池 瑛, 齋藤 心, 千葉 蒔七, 風當 ゆりえ, 倉科 健太郎, 金丸 理人, 松本 志郎, 高橋 和也, 金子 勇貴, 細谷 好則, 北山 丈二, 佐田 尚宏, 岡田 健太, 春田 英律
    日本外科学会定期学術集会抄録集 122回 RS-4 2022年4月  
  • 川平 洋, 鈴木 義彦, 前田 佳孝, 兼田 裕司, 太田 学, 松本 志郎, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 122回 DP-6 2022年4月  
  • 太田 学, 川平 洋, 千葉 蒔七, 篠原 翔一, 窪木 大悟, 松本 志郎, 兼田 裕司, 塩澤 幹雄, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 122回 DP-6 2022年4月  
  • 太白 健一, 遠藤 和洋, 森嶋 計, 笹沼 英紀, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, Alan Lefor, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 122回 DP-7 2022年4月  
  • 山崎 浩宣, 齋藤 心, 春田 英律, 小池 瑛, 千葉 小夜, 千葉 蒔七, 岡田 健太, 鈴木 昭広, 橋本 愛, 山野井 徳子, 北山 丈二, 細谷 好則, 佐田 尚宏
    肥満研究 27(Suppl.) 353-353 2022年3月  
  • 小池 瑛, 齋藤 心, 春田 英律, 岡田 健太, 石橋 俊, 倉科 憲太郎, 橋本 愛, 山野井 徳子, 芝 順太郎, 鈴木 昭広, 竹内 護, 千葉 蒔七, 千葉 小夜, 金子 勇貴, 高橋 和也, 北山 丈二, Lefor Alan K., 細谷 好則, 佐田 尚宏
    自治医科大学紀要 44 15-20 2022年3月  
    【目的】高度肥満症患者に対する減量・代謝改善手術症例の治療効果を検討する。【方法】2010年7月から2021年3月までに当院で行った107回(103症例)の減量・代謝改善手術を対象とした。主に体重変化と糖尿病治療効果を後ろ向きに評価した。【結果】99症例がデータ解析可能であった。術後総体重減少率は、術後1年目で28.4%、2年目で28.3%、5年目で27.3%であり、約30%の体重減少効果を認めた。糖尿病患者は47例であり、HbA1cの推移は術前の6.8%±1.4から術後6ヵ月で5.9%(±0.8)、術後1年で5.8%(±0.93)と改善を認めた。糖尿病寛解率は、術後6ヵ月で65.9%、術後1年で76.5%、術後4年で50.0%であり、糖尿病患者の半数で寛解を認めた。術前インスリン非使用群でインスリン使用群より糖尿病寛解率が良好な傾向が認められた。また、術前mABCDスコアが高い症例ほど術後寛解度が高かった。【結語】当院での減量・代謝改善手術症例において比較的良好な減量効果・糖尿病治療効果が得られた。(著者抄録)
  • 高橋 和也, 大澤 英之, 金丸 理人, 倉科 憲太郎, 齋藤 心, 山口 博紀, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本胃癌学会総会記事 94回 255-255 2022年3月  
  • 松浦 博和, 金丸 理人, 金子 勇貴, 高橋 和也, 高木 徹, 倉科 憲太郎, 齋藤 心, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本胃癌学会総会記事 94回 416-416 2022年3月  
  • Yukihiro Sanada, Yasunaru Sakuma, Yasuharu Onishi, Noriki Okada, Yuta Hirata, Toshio Horiuchi, Takahiko Omameuda, Koshi Matsumoto, Alan Kawarai Lefor, Naohiro Sata
    Transplant immunology 71 101557-101557 2022年2月23日  
    BACKGROUND: Sinusoidal obstruction syndrome (SOS) after liver transplantation (LT) is a rare and potentially lethal complication. We retrospectively reviewed the outcomes of patients with post-transplant SOS. METHODS: Between May 2001 and December 2019, of 332 patients who underwent LT, 5 (1.5%) developed SOS. The median age at LT was 1.7 years (range 0.1-66.5). SOS was histopathologically diagnosed and classified as early-onset (<1 month) or late-onset. RESULTS: The median time to diagnosis of SOS was one month after LT. All patients developed acute cellular rejection before SOS, and the cause of SOS was acute cellular rejection in four patients and unknown in one. The treatment of SOS included conversion to tacrolimus from cyclosporine, intrahepatic hepatic vein stent placement, strengthening of immunosuppression, and plasma exchange. The 5-year graft survival rates in patients with and without SOS were 53.0% and 92.5%, respectively (p < 0.001). Of three patients with early-onset SOS, two patients improved and are doing well, and one patient died of graft failure four months after LT. CONCLUSIONS: The cause and treatment of post-transplant SOS are not yet defined. The poor outcomes in patients with early-onset SOS may be improved by strengthening of immunosuppression. Patients with late-onset SOS are ultimately treated by repeat LT.
  • Jun Watanabe, Ryota Matsui, Hideki Sasanuma, Yoichi Ishizaki, Tetsu Fukunaga, Kazuhiko Kotani, Naohiro Sata
    Clinical Nutrition 41(2) 321-328 2022年2月  
  • Hiroshi Maeda, Kouichi Miura, Naoki Morimoto, Shunji Watanabe, Mamiko Tsukui, Yoshinari Takaoka, Hiroaki Nomoto, Rie Goka, Naoto Sato, Kazue Morishima, Yasunaru Sakuma, Naohiro Sata, Noriyoshi Fukushima, Norio Isoda, Hironori Yamamoto
    Cancers 14(3) 2022年1月31日  
    BACKGROUND: Conventional therapies, including chemoembolization and radiation therapy, have been expected to prolong the prognosis of hepatocellular carcinoma (HCC) patients with extrahepatic metastases, which remains poor. However, little information is available on the efficacy of conventional therapies for such patients under tyrosine kinase inhibitor (TKI) treatment. METHODS: We retrospectively investigated 127 HCC patients with extrahepatic metastases, who were divided into the non-TKI (conventional therapies) and TKI groups and further subdivided into the TKI alone and TKI plus conventional therapies groups. Conventional therapies included transcatheter arterial chemoembolization, cisplatin-based chemotherapy, radiation, surgery, and UFT, an oral chemotherapeutic agent. RESULTS: The median of the overall survival (OS) of the 127 patients with extrahepatic metastases was 7.0 months. Meanwhile, the median OS of the TKI and non-TKI groups was 12.1 and 4.1 months, respectively. Imitating TKI after diagnosing metastases promoted a favorable increase in OS. Among the TKI group, the median OS in the TKI alone group was 8.9 months. TKI plus conventional therapies promoted no improvement in OS after adjusting for the patients' background data. CONCLUSION: TKI promoted a better OS in HCC patients with extrahepatic metastases compared to conventional therapies. However, TKI plus conventional therapies promoted no improvement in the prognosis of such patients.
  • Jun Watanabe, Kazuma Rifu, Hideki Sasanuma, Kazuhiko Kotani, Naohiro Sata
    Journal of Hepato-Biliary-Pancreatic Sciences 2022年1月28日  
  • Yukihiro Sanada, Yasunaru Sakuma, Yasuharu Onishi, Noriki Okada, Yuta Hirata, Toshio Horiuchi, Takahiko Omameuda, Alan Kawarai Lefor, Naohiro Sata
    Surgery 171(6) 1671-1676 2022年1月10日  
    BACKGROUND: There is no consensus about long-term outcomes in patients with biliary atresia. We retrospectively reviewed the long-term outcomes in pediatric patients who underwent living donor liver transplantation for biliary atresia. METHODS: Between May 2001 and December 2020, 221 (73%) of 302 pediatric patients who underwent living donor liver transplantation had biliary atresia. The median age at living donor liver transplantation was 1.2 (range 0.2-16.5) years, and follow-up was 10.3 ± 5.5 years. RESULTS: The 10-year graft survival rates in patients with and without biliary atresia were 94% and 89%, respectively (P = .019). The 10-year graft survival was significantly poorer in patients ≥12 years of age (84%) versus those <12 years of age at living donor liver transplantation (0-2 years: 95%; 2-12 years: 96%) (P = .016). The causes of graft failure in patients with biliary atresia included late-onset refractory rejection (n = 6), bowel perforation (n = 2), and acute encephalitis (n = 2), as well as cerebral hemorrhage, hepatic vein thrombosis, and sepsis (n = 1 for all). All 7 patients with graft failure due to refractory rejection and hepatic vein thrombosis underwent repeated liver transplantation and are alive in 2021. The rates of post-transplant portal vein complications and early-onset acute cellular rejection in patients with biliary atresia were higher than in those without biliary atresia (P = .042 and P = .022, respectively). In 2021, of 60 adolescents with biliary atresia, 14 (23%) reported medication nonadherence. The rate of liver dysfunction due to late-onset acute cellular rejection and graft failure due to late-onset refractory rejection in patients with nonadherence was higher than in patients with satisfactory adherence (P = .009). CONCLUSION: The long-term prognosis after living donor liver transplantation in pediatric patients with biliary atresia is quite good. However, long-term support to enhance medication adherence is required in adolescents with biliary atresia.
  • Jun Watanabe, Kazuma Rifu, Takehiro Kagaya, Kazuhiko Kotani, Naohiro Sata
    Surgery Today 2022年1月8日  
  • Yuki Kimura, Hideyuki Ohzawa, Hideyo Miyato, Yuki Kaneko, Akira Saito, Kazuya Takahashi, Mineyuki Tojo, Hironori Yamaguchi, Kentaro Kurashina, Shin Saito, Yoshinori Hosoya, Alan Kawarai Lefor, Naohiro Sata, Joji Kitayama
    Scientific reports 12(1) 205-205 2022年1月7日  
    Peritoneal dissemination is a major metastatic pathway for gastrointestinal and ovarian malignancies. The miR-29b family is downregulated in peritoneal fluids in patients with peritoneal metastases (PM). We examined the effect of miR-29b on mesothelial cells (MC) which play critical a role in the development of PM through mesothelial-mesenchymal transition (MMT). Human peritoneal mesothelial cells (HPMCs) were isolated from surgically resected omental tissue and MMT induced by stimulation with 10 ng/ml TGF-β1. MiR-29b mimics and negative control miR were transfected by lipofection using RNAiMAX and the effects on the MMT evaluated in vitro. HPMC produced substantial amounts of miR-29b which was markedly inhibited by TGF-β1. TGF-β1 stimulation of HPMC induced morphological changes with decreased expression of E-cadherin and calretinin, and increased expression of vimentin and fibronectin. TGF-β1 also enhanced proliferation and migration of HPMC as well as adhesion of tumor cells in a fibronectin dependent manner. However, all events were strongly abrogated by simultaneous transfection of miR-29b. MiR-29b inhibits TGF-β1 induced MMT and replacement of miR-29b in the peritoneal cavity might be effective to prevent development of PM partly through the effects on MC.
  • 齋藤 心, 春田 英律, 千葉 蒔七, 千葉 小夜, 小池 瑛, 細谷 好則, 倉科 憲太郎, 岡田 健太, 北山 丈二, 佐田 尚宏
    日本成人病(生活習慣病)学会会誌 47 72-72 2022年1月  
  • 齋藤 晶, 大澤 英之, 田村 昂平, 金子 勇貴, 風當 ゆりえ, 高橋 和也, 木村 有希, 東條 峰之, 宮戸 秀世, 佐田 尚宏, 北山 丈二
    日本成人病(生活習慣病)学会会誌 47 75-75 2022年1月  
  • Yukihiro Sanada, Yasunaru Sakuma, Yasuharu Onishi, Noriki Okada, Yuta Hirata, Toshio Horiuchi, Takahiko Omameuda, Alan Kawarai Lefor, Naohiro Sata
    Transplant international : official journal of the European Society for Organ Transplantation 35 10220-10220 2022年  
    There is little information about the outcomes of pediatric patients with hepatolithiasis after living donor liver transplantation (LDLT). We retrospectively reviewed hepatolithiasis after pediatric LDLT. Between May 2001 and December 2020, 310 pediatric patients underwent LDLT with hepaticojejunostomy. Treatment for 57 patients (18%) with post-transplant biliary strictures included interventions through double-balloon enteroscopy (DBE) in 100 times, percutaneous transhepatic biliary drainage (PTBD) in 43, surgical re-anastomosis in 4, and repeat liver transplantation in 3. The median age and interval at treatment were 12.3 years old and 2.4 years after LDLT, respectively. At the time of treatments, 23 patients (7%) had developed hepatolithiasis of whom 12 (52%) were diagnosed by computed tomography before treatment. Treatment for hepatolithiasis included intervention through DBE performed 34 times and PTBD 6, including lithotripsy by catheter 23 times, removal of plastic stent in 8, natural exclusion after balloon dilatation in 7, and impossibility of removal in 2. The incidence of recurrent hepatolithiasis was 30%. The 15-years graft survival rates in patients with and without hepatolithiasis were 91% and 89%, respectively (p = 0.860). Although hepatolithiasis after pediatric LDLT can be treated using interventions through DBE or PTBD and its long-term prognosis is good, the recurrence rate is somewhat high.
  • 小泉 大, 下平 健太郎, 青木 裕一, 目黒 由行, 森嶋 計, 兼田 裕司, 三木 厚, 遠藤 和洋, 笹沼 英紀, 佐田 尚宏
    消化器内視鏡 34(1) 119-124 2022年1月  
  • 清水 敦, 倉科 憲太郎, 笹沼 英紀, 遠藤 俊輔, 大槻 マミ太郎, 村上 礼子, 春山 早苗, 渡井 恵, 大柴 幸子, 佐田 尚宏
    日本外科学会雑誌 123(1) 112-114 2022年1月  
  • Kazuya Takahashi, Kentaro Kurashina, Hironori Yamaguchi, Rihito Kanamaru, Hideyuki Ohzawa, Hideyo Miyato, Shin Saito, Yoshinori Hosoya, Alan Kawarai Lefor, Naohiro Sata, Joji Kitayama
    Frontiers in immunology 13 969468-969468 2022年  
    Background: The peritoneal cavity contains many site-specific immune cells which constitute a unique immune microenvironment. However, it is unclear how the local immune signature is altered in patients with peritoneal metastases (PM). Methods: Peritoneal lavage fluid or ascites were obtained from 122 patients with various stages of gastric cancer (GC). Cells recovered from peritoneal fluids were immunostained with mAbs for lymphocyte-, macrophage- and tumor cell-specific antigens and the frequencies of leukocyte subsets and antigen expression levels were evaluated with multi-color flowcytometry. Results: The proportions of CD8(+) T cells, CD3(+)CD56(+) NKT-like cells, and CD3(-)CD56(+) NK cells to CD45(+) leukocytes were significantly reduced in patients with PM compared to those without PM. In patients with PM, the rates of CD8 (+) T cells and NKT-like cells correlated inversely with the tumor leukocyte ratio (TLR), the relative frequency of CD326(+) tumor cells to CD45(+) leukocytes. In contrast, the proportion of CD19(+) B cells was significantly increased in patients with PM, and their proportion correlated positively with the TLR and peritoneal carcinomatosis index (PCI) score. In patients with PM, CD14(+) macrophages tended to be increased with enhanced expression of CD14, CD16 and a M2-macrophage marker, CD163. In particular, macrophages in patients with high TLR contained many granules with high side scatter and CD14 expression in their flow profile compared to those without PM. Conclusion: PM are accompanied by a drastic change in phenotypes of lymphocyte and macrophage in the peritoneal cavity, which might be involved in the development and progression of intraperitoneal tumor growth.
  • YUKO KUMAGAI, YURIE FUTOH, HIDEYO MIYATO, HIDEYUKI OHZAWA, HIRONORI YAMAGUCHI, SHIN SAITO, KENTARO KURASHINA, YOSHINORI HOSOYA, ALAN KAWARAI LEFOR, NAOHIRO SATA, JOJI KITAYAMA
    In Vivo 36(3) 1126-1135 2022年  
  • 清水 敦, 倉科 憲太郎, 笹沼 英紀, 遠藤 俊輔, 大槻 マミ太郎, 村上 礼子, 春山 早苗, 渡井 恵, 大柴 幸子, 佐田 尚宏
    日本外科学会雑誌 123(1) 112-114 2022年1月  
  • Jun Watanabe, Atsushi Miki, Masaru Koizumi, Kazuhiko Kotani, Naohiro Sata
    Nutrients 13(12) 4394 2021年12月7日  査読有り
    Background: Previous systematic reviews have not clarified the effect of postoperative coffee consumption on the incidence of postoperative ileus (POI) and the length of hospital stay (LOS). We aimed to assess its effect on these postoperative outcomes. Methods: Studies evaluating postoperative coffee consumption were searched using electronic databases until September 2021 to perform random-effect meta-analysis. The quality of evidence was assessed using the Cochrane risk-of-bias tool. Caffeinated and decaffeinated coffee were also compared. Results: Thirteen trials (1246 patients) and nine ongoing trials were included. Of the 13 trials, 6 were on colorectal surgery, 5 on caesarean section, and 2 on gynecological surgery. Coffee reduced the time to first defecation (mean difference (MD) −10.1 min; 95% confidence interval (CI) = −14.5 to −5.6), POI (risk ratio 0.42; 95% CI = 0.26 to 0.69); and LOS (MD −1.5; 95% CI = −2.7 to −0.3). This trend was similar in colorectal and gynecological surgeries. Coffee had no adverse effects. There was no difference in POI or LOS between caffeinated and decaffeinated coffee (p > 0.05). The certainty of evidence was low to moderate. Conclusion: This review showed that postoperative coffee consumption, regardless of caffeine content, likely reduces POI and LOS after colorectal and gynecological surgery.
  • 笹沼 英紀, 佐田 尚宏, 下平 健太郎, 青木 裕一, 目黒 由行, 宮戸 秀世, 森嶋 計, 三木 厚, 遠藤 和洋, 小泉 大, 吉田 淳, 佐久間 康成, 北山 丈二, 瓦井Lefor Alan
    膵臓 36(6) 351-359 2021年12月  
    膵全摘では周術期血糖・栄養管理が重要である.12年間の膵全摘32例の周術期血糖・栄養状態を検討した.一期的・二期的膵全摘は各々16例で計48病変の約80%を膵管内乳頭粘液性腫瘍と浸潤性膵管癌が占めた.5年生存率は60.2%,一期的・二期的膵全摘で差はなかった.HbA1cは術前6.7%,術後1年は7.7%と上昇,prognostic nutritional index(PNI)は術前47.8,術後1年は43.0と低下した.予後因子を単変量解析すると術後1年neutrophil-lymphocyte ratio,術前platelet-lymphocyte ratio,術後1年PNIが抽出され,多変量解析では術後1年PNIが有意な因子であった.術後1年PNI 40.5未満は予後不良で,高力価パンクレアチン製剤投与群は予後良好であった.膵全摘後は正しい病態把握のもとに内外分泌治療を行うことが重要である.(著者抄録)
  • 結城 智仁, 牛尾 純, 菅野 敦, 池田 恵理子, 安藤 梢, 三輪田 哲郎, 長井 洋樹, 川崎 佑輝, 横山 健介, 沼尾 規且, 玉田 喜一, 笹沼 英紀, 福嶋 敬宜, 佐田 尚宏
    膵臓 36(6) 366-376 2021年12月  
    症例は57歳男性.検診で膵体部の嚢胞性病変が指摘され,当院を紹介された.造影CTでは膵体部に17mm大の中心部に嚢胞成分を伴う充実性腫瘤が認められた.3年後の造影CTでは,嚢胞成分を伴いながら23mm大に腫瘍径が増大し,MRIでは中心部の嚢胞成分はT1WI,T2WIともに高信号を示し,辺縁は拡散低下を伴う充実成分として観察された.超音波内視鏡検査でも同様に,中心に嚢胞成分を伴う充実性腫瘤として観察された.膵体尾部切除が施行され,病理学的にmixed acinar-neuroendocrine carcinoma(MAcNEC)と診断された.腫瘍中央の嚢胞成分は壊死によるものが疑われ,その周囲にsynaptophysin陽性の領域が,更にその周囲にBCL10,trypsin陽性の領域が分かれて確認された.本症例はMAcNECの発生様式を考察する上で示唆に富む症例であり,文献的考察を加え報告する.(著者抄録)
  • 結城 智仁, 牛尾 純, 菅野 敦, 池田 恵理子, 安藤 梢, 三輪田 哲郎, 長井 洋樹, 川崎 佑輝, 横山 健介, 沼尾 規且, 玉田 喜一, 笹沼 英紀, 福嶋 敬宜, 佐田 尚宏
    膵臓 36(6) 366-376 2021年12月  
    症例は57歳男性.検診で膵体部の嚢胞性病変が指摘され,当院を紹介された.造影CTでは膵体部に17mm大の中心部に嚢胞成分を伴う充実性腫瘤が認められた.3年後の造影CTでは,嚢胞成分を伴いながら23mm大に腫瘍径が増大し,MRIでは中心部の嚢胞成分はT1WI,T2WIともに高信号を示し,辺縁は拡散低下を伴う充実成分として観察された.超音波内視鏡検査でも同様に,中心に嚢胞成分を伴う充実性腫瘤として観察された.膵体尾部切除が施行され,病理学的にmixed acinar-neuroendocrine carcinoma(MAcNEC)と診断された.腫瘍中央の嚢胞成分は壊死によるものが疑われ,その周囲にsynaptophysin陽性の領域が,更にその周囲にBCL10,trypsin陽性の領域が分かれて確認された.本症例はMAcNECの発生様式を考察する上で示唆に富む症例であり,文献的考察を加え報告する.(著者抄録)
  • 笹沼 英紀, 佐田 尚宏, 下平 健太郎, 青木 裕一, 目黒 由行, 宮戸 秀世, 森嶋 計, 三木 厚, 遠藤 和洋, 小泉 大, 吉田 淳, 佐久間 康成, 北山 丈二, 瓦井Lefor Alan
    膵臓 36(6) 351-359 2021年12月  
  • 須藤 慧多, 下平 健太郎, 青木 裕一, 目黒 由行, 森嶋 計, 笹沼 英紀, 佐久間 康成, 北山 丈二, 佐田 尚宏
    日本消化器病学会関東支部例会プログラム・抄録集 367回 38-38 2021年12月  
  • 小池 瑛, 齋藤 心, 春田 英律, 千葉 蒔七, 風當 ゆりえ, 倉科 憲太郎, 松本 志郎, 金丸 理人, 高橋 和也, 金子 勇貴, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本消化器外科学会雑誌 54(Suppl.2) 167-167 2021年11月  
  • Takumi Teratani, Naoya Kasahara, Tetsuo Ijichi, Yasuhiro Fujimoto, Yasunaru Sakuma, Naohiro Sata, Joji Kitayama
    Amino Acids 2021年10月15日  
    <title>Abstract</title>Polyamines are important to the survival and activation of organs and tissues via a homeostatic cell-metabolic process, and the polyamine content in cytoplasm decreases with aging. Decreases in cellular polyamine have been known to augment mutagenesis and cell death. Thus, supplementary polyamine in food is important to the prevention of aging. Here we show the anti-aging effects of oral intake of polyamine using luciferase-transgenic rats. Healthy rats, 10–12 weeks old, were given foods containing 0.01% and 0.1% (w/w) of polyamine, as compared a control food without polyamine, for 4 weeks. Using a bioimaging system, the photon intensities seen in the whole bodies and livers of rats consuming 0.1% of polyamine in food were stronger than those in rats consuming 0.01% and 0% of polyamine. However, there were no differences between groups in other characteristics, such as liver damage and body weight. In conclusion, we found that polyamine intake can activate cells throughout the whole body, providing an anti-aging effect.
  • Yoshihiko Kono, Ryo Inoue, Takumi Teratani, Mineyuki Tojo, Yuko Kumagai, So Morishima, Koji Koinuma, Alan Kawarai Lefor, Joji Kitayama, Naohiro Sata, Hisanaga Horie
    Digestion 1-9 2021年10月7日  
    BACKGROUND/AIMS: Recent studies have demonstrated that the populations of several microbes are significantly increased in fecal samples from patients with colorectal cancer (CRC), suggesting their involvement in the development of CRC. The aim of this study was to identify microbes which are increased in distal CRCs and to identify the specific location of microbes increased in mucosal tissue around the tumor. METHODS: Tissue specimens were collected from surgical resections of 28 distal CRCs. Five samples were collected from each specimen (location A: tumor, B: adjacent normal mucosa, C: normal mucosa 1 cm proximal to the tumor, D: normal mucosa 3 cm proximally, and E: normal mucosa 6 cm proximally). The microbiota in the sample were analyzed using 16S rRNA gene amplicon sequencing and the relative abundance (RA) of microbiota compared among the 5 locations. RESULTS: At the genus level, the RA of Fusobacterium and Streptococcus at location A was the highest among the 5 locations, significantly different from that in location E. The dominant species of each genus was Fusobacterium nucleatum and Streptococcus anginosus. The RAs of these species gradually decreased from locations B to E with a statistically significant difference in F. nucleatum. The genus Peptostreptococcus also showed a similar trend, and the RA of Peptostreptococcus stomatis in location A was significantly associated with depth of tumor invasion and tumor size. CONCLUSION: Although the clinical relevance is not clear yet, these results suggest that F. nucleatum, S. anginosus, and P. stomatis can spread to the adjacent normal tissues and may change the surrounding microenvironment to support the progression of CRC.
  • 東條 峰之, 津久井 秀則, 金子 勇貴, 風當 ゆりえ, 木村 有希, 高橋 和也, 齋藤 晶, 大澤 英之, 宮戸 秀世, 鯉沼 広治, 堀江 久永, 佐田 尚宏, 北山 丈二
    日本癌治療学会学術集会抄録集 59回 O57-4 2021年10月  
  • 田原 真紀子, 堀江 久永, 笹沼 英紀, 鯉沼 広治, 熊谷 祐子, 太白 健一, 太田 学, 井上 賢之, 山口 博紀, 佐久間 康成, 川平 洋, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 82(増刊) S491-S491 2021年10月  
  • 目黒 由行, 笹沼 英紀, 池田 恵理子, 藤原 正貴, 下平 健太郎, 青木 裕一, 太白 健一, 佐田友 藍, 森嶋 計, 遠藤 和洋, 佐久間 康成, 福嶋 敬宜, 堀江 久永, 佐田 尚宏
    日本消化器病学会雑誌 118(臨増大会) A718-A718 2021年10月  
  • 林 宏樹, 横山 健介, 菅野 敦, 長井 洋樹, 池田 恵理子, 沼尾 規且, 牛尾 純, 天野 雄介, 笹沼 英紀, 玉田 喜一, 福嶋 敬宜, 佐田 尚宏
    胆道 35(4) 668-677 2021年10月  
    症例は72歳男性.膀胱癌術後の経過観察目的に施行した造影CTにて胆嚢底部の壁肥厚が指摘され当科を受診した.造影CTやMRIでは胆嚢底部に造影効果を示す隆起性病変と連続する壁肥厚が認められた.EUSでは,広基性の隆起性病変における外側高エコー層の不整が認められた.ERCP時の胆汁細胞診から腺癌を認め,拡大胆嚢摘出術が施行された.肉眼所見では大小不同の顆粒状粘膜を伴う壁肥厚性病変と,隆起性病変の一部と考えられる脱落した組織片が確認された.病理所見では肥厚した胆嚢壁と一致して管状腺癌と神経内分泌癌の所見が認められ,混合型神経内分泌癌と診断した.また脱落した組織には腺癌と肉腫が混在していた.胆嚢における腺癌,神経内分泌癌,肉腫が混ずる腫瘍は稀と考えられた.神経内分泌癌と癌肉腫の進展様式のまとめから,混合する腫瘍成分の影響により隆起性病変と壁肥厚性病変が混在する特異的な形態を呈した可能性が示唆された.(著者抄録)
  • 目黒 由行, 笹沼 英紀, 池田 恵理子, 藤原 正貴, 下平 健太郎, 青木 裕一, 太白 健一, 佐田友 藍, 森嶋 計, 遠藤 和洋, 佐久間 康成, 福嶋 敬宜, 堀江 久永, 佐田 尚宏
    日本消化器病学会雑誌 118(臨増大会) A718-A718 2021年10月  
  • 金子 勇貴, 大澤 英之, 高橋 和也, 金丸 理人, 倉科 憲太郎, 宮戸 秀世, 齋藤 心, 山口 博紀, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本癌治療学会学術集会抄録集 59回 O31-5 2021年10月  
  • 高橋 和也, 大澤 英之, 金丸 理人, 倉科 憲太郎, 齋藤 心, 山口 博紀, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本癌治療学会学術集会抄録集 59回 O46-3 2021年10月  
  • 鯉沼 広治, 笹沼 英紀, 堀江 久永, 佐田 尚宏
    カレントテラピー 39(10) 958-963 2021年10月  
    大腸癌の血行性転移には、肝転移、肺転移、その他(脳、骨、副腎など)がある。肝転移と肺転移は、治癒切除により予後改善効果が報告されており、多発転移であっても他臓器に転移を認めない場合は、治癒切除可能かどうかを注意深く見極めることが重要である。また近年の化学療法の進歩により、初診時には切除不能な肝転移であっても、化学療法後の縮小により切除可能となる場合がある。切除後の予後ははじめから切除可能な肝転移のそれとほぼ同等とされ、このconversion therapyは多発肝転移を有する進行大腸癌に対する治療戦略のひとつとして確立されている。肺転移についても、一定の条件を満たす症例では切除により予後の改善が報告されており、近年の胸腔鏡手術の技術や器機の進歩により、両葉や多発病変の切除も可能となっている。ただし肺転移切除の治療成績については大規模研究の報告が少なく、ほとんどが後ろ向き研究であることから、今後の研究結果の集積が待たれる。(著者抄録)
  • 林 宏樹, 横山 健介, 菅野 敦, 長井 洋樹, 池田 恵理子, 沼尾 規且, 牛尾 純, 天野 雄介, 笹沼 英紀, 玉田 喜一, 福嶋 敬宜, 佐田 尚宏
    胆道 35(4) 668-677 2021年10月  
  • Yukihiro Sanada, Yasunaru Sakuma, Yasuharu Onishi, Noriki Okada, Naoya Yamada, Yuta Hirata, Go Miyahara, Takumi Katano, Toshio Horiuchi, Takahiko Omameuda, Alan Kawarai Lefor, Naohiro Sata
    Annals of transplantation 26 e932994 2021年10月1日  
    BACKGROUND There is no consensus about the long-term prognosis of pediatric patients with a variety of rare liver diseases but with inherited metabolic diseases (IMDs). We retrospectively reviewed the developmental outcomes of patients with IMDs undergoing living donor liver transplantation (LDLT). MATERIAL AND METHODS Between May 2001 and December 2020, of 314 pediatric patients who underwent LDLT, 44 (14%) had IMDs. The median age at LDLT was 3.0 years old (range 0-15.0 years). Associations between the post-transplant complications and graft survival rate in patients with IMDs and biliary atresia (BA) were calculated. We evaluated the safety of LDLT from heterozygous carrier donors, the prognosis of patients with IMDs who have metabolic defects expressed in other organs, and developmental outcomes of patients with IMDs. RESULTS The 10-year graft survival rates in patients with IMDs and BA were 87% and 94%, respectively (P=0.041), and the causes of graft failure included pneumocystis pneumonia, acute lung failure, hemophagocytic syndrome, hepatic vein thrombosis, portal vein thrombosis, and sepsis. The rate of post-transplant cytomegalovirus viremia in patients with IMDs was higher than that of patients with BA (P=0.039). Of 39 patients with IMDs, 15 patients (38%) had severe motor and intellectual disabilities in 4 patients, intellectual developmental disorders including epilepsy in 2, and attention-deficit hyperactivity disorder in 2. Of 28 patients with IMDs, 13 (46%) needed special education. CONCLUSIONS The long-term outcomes of LDLT in patients with IMDs are good. However, further long-term social and educational follow-up regarding intellectual developmental disorders is needed.
  • 鯉沼 広治, 笹沼 英紀, 堀江 久永, 佐田 尚宏
    カレントテラピー 39(10) 958-963 2021年10月  
    大腸癌の血行性転移には、肝転移、肺転移、その他(脳、骨、副腎など)がある。肝転移と肺転移は、治癒切除により予後改善効果が報告されており、多発転移であっても他臓器に転移を認めない場合は、治癒切除可能かどうかを注意深く見極めることが重要である。また近年の化学療法の進歩により、初診時には切除不能な肝転移であっても、化学療法後の縮小により切除可能となる場合がある。切除後の予後ははじめから切除可能な肝転移のそれとほぼ同等とされ、このconversion therapyは多発肝転移を有する進行大腸癌に対する治療戦略のひとつとして確立されている。肺転移についても、一定の条件を満たす症例では切除により予後の改善が報告されており、近年の胸腔鏡手術の技術や器機の進歩により、両葉や多発病変の切除も可能となっている。ただし肺転移切除の治療成績については大規模研究の報告が少なく、ほとんどが後ろ向き研究であることから、今後の研究結果の集積が待たれる。(著者抄録)
  • Daishi Naoi, Hisanaga Horie, Koji Koinuma, Yuko Kumagai, Gaku Ota, Mineyuki Tojo, Yuji Kaneda, Shuji Hishikawa, Ai Sadatomo, Yoshiyuki Inoue, Noriyoshi Fukushima, Alan Kawarai Lefor, Naohiro Sata
    Surgery today 51(10) 1713-1719 2021年10月  
    PURPOSE: The aim of this study was to evaluate both the intestinal mucosa staple line integrity and anastomotic leak pressure after healing in a porcine survival model. METHODS: We used two suture models using two different size staples (incomplete mucosal closure model: group G [staple height 0.75 mm], complete mucosal closure model: group B [staple height 1.5 mm]) in the porcine ileum. Five staple lines were created in each group made in the ileum for each model, and the staple sites harvested on days 0, 2, and 7. The leak pressure at the staple site was measured at each time point. RESULTS: On day 0, the leak pressure for group G (79.5 mmHg) was significantly lower than that for group B (182.3 mmHg) (p < 0.01). On days 2 and 7, there was no significant difference between groups G and B (171 mmHg and 175.5 mmHg on day 2, 175.5 mmHg and 175.5 mmHg on day 7, p > 0.05). The histological findings in both groups showed similar healing at postoperative days 2 and 7. CONCLUSION: The integrity of the mucosal staple lines was associated with the postoperative leak pressure on day 0. However, there was no association with the leak pressure at two days or more postoperatively in a porcine model.
  • 木村 有希, 大澤 英之, 金子 勇貴, 風當 ゆりえ, 田村 昂平, 高橋 和也, 齋藤 晶, 東條 峰之, 宮戸 秀世, 佐田 尚宏, 北山 丈二
    日本癌学会総会記事 80回 [J10-5] 2021年9月  
  • 風當 ゆりえ, 北山 丈二, 田村 昂平, 金子 勇貴, 高橋 和也, 木村 有希, 齋藤 晶, 東條 峰之, 大澤 英之, 宮戸 秀世, 山口 博紀, 佐田 尚宏
    日本癌学会総会記事 80回 [P12-5] 2021年9月  

MISC

 516

講演・口頭発表等

 975

所属学協会

 10

共同研究・競争的資金等の研究課題

 17